CORD-19:2008f024274c53b0de1276f4047a6a641813fd98 / 545406-545939 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T32968","span":{"begin":0,"end":533},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The charts of 219 patients of an estimated 530(41%), 109(50%) with allergic rhinitis only and 116 (53%) with concomitant asthma, were retrospectively or prospectively reviewed who had been on immunotherapy to inhalants for 6 months to 6 years, mean 2.7 years, age range 7y-64y, mean 25y, 108 male(49%), 111 female(51%) with 213 caucasian (97%), 2 oriental (1%) and 4(2%) Afroamericans .They completed symptom and medication survey (1) every 6 months with range of improvement using a decline in Likert scale (+)20 to (-)104, mean 24."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T80","span":{"begin":0,"end":533},"obj":"Sentence"}],"text":"The charts of 219 patients of an estimated 530(41%), 109(50%) with allergic rhinitis only and 116 (53%) with concomitant asthma, were retrospectively or prospectively reviewed who had been on immunotherapy to inhalants for 6 months to 6 years, mean 2.7 years, age range 7y-64y, mean 25y, 108 male(49%), 111 female(51%) with 213 caucasian (97%), 2 oriental (1%) and 4(2%) Afroamericans .They completed symptom and medication survey (1) every 6 months with range of improvement using a decline in Likert scale (+)20 to (-)104, mean 24."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T5213","span":{"begin":67,"end":84},"obj":"Disease"},{"id":"T5214","span":{"begin":67,"end":75},"obj":"Disease"},{"id":"T5215","span":{"begin":76,"end":84},"obj":"Disease"},{"id":"T5216","span":{"begin":121,"end":127},"obj":"Disease"}],"attributes":[{"id":"A5213","pred":"mondo_id","subj":"T5213","obj":"http://purl.obolibrary.org/obo/MONDO_0011786"},{"id":"A5214","pred":"mondo_id","subj":"T5214","obj":"http://purl.obolibrary.org/obo/MONDO_0004980"},{"id":"A5215","pred":"mondo_id","subj":"T5215","obj":"http://purl.obolibrary.org/obo/MONDO_0003014"},{"id":"A5216","pred":"mondo_id","subj":"T5216","obj":"http://purl.obolibrary.org/obo/MONDO_0004979"}],"text":"The charts of 219 patients of an estimated 530(41%), 109(50%) with allergic rhinitis only and 116 (53%) with concomitant asthma, were retrospectively or prospectively reviewed who had been on immunotherapy to inhalants for 6 months to 6 years, mean 2.7 years, age range 7y-64y, mean 25y, 108 male(49%), 111 female(51%) with 213 caucasian (97%), 2 oriental (1%) and 4(2%) Afroamericans .They completed symptom and medication survey (1) every 6 months with range of improvement using a decline in Likert scale (+)20 to (-)104, mean 24."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T2851","span":{"begin":67,"end":84},"obj":"Phenotype"},{"id":"T2852","span":{"begin":121,"end":127},"obj":"Phenotype"}],"attributes":[{"id":"A2851","pred":"hp_id","subj":"T2851","obj":"http://purl.obolibrary.org/obo/HP_0003193"},{"id":"A2852","pred":"hp_id","subj":"T2852","obj":"http://purl.obolibrary.org/obo/HP_0002099"}],"text":"The charts of 219 patients of an estimated 530(41%), 109(50%) with allergic rhinitis only and 116 (53%) with concomitant asthma, were retrospectively or prospectively reviewed who had been on immunotherapy to inhalants for 6 months to 6 years, mean 2.7 years, age range 7y-64y, mean 25y, 108 male(49%), 111 female(51%) with 213 caucasian (97%), 2 oriental (1%) and 4(2%) Afroamericans .They completed symptom and medication survey (1) every 6 months with range of improvement using a decline in Likert scale (+)20 to (-)104, mean 24."}

{"project":"CORD-19-PD-UBERON","denotations":[{"id":"T1105","span":{"begin":502,"end":507},"obj":"Body_part"}],"attributes":[{"id":"A1105","pred":"uberon_id","subj":"T1105","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"The charts of 219 patients of an estimated 530(41%), 109(50%) with allergic rhinitis only and 116 (53%) with concomitant asthma, were retrospectively or prospectively reviewed who had been on immunotherapy to inhalants for 6 months to 6 years, mean 2.7 years, age range 7y-64y, mean 25y, 108 male(49%), 111 female(51%) with 213 caucasian (97%), 2 oriental (1%) and 4(2%) Afroamericans .They completed symptom and medication survey (1) every 6 months with range of improvement using a decline in Likert scale (+)20 to (-)104, mean 24."}